

Beginning **Tuesday, February 4, 2025**, the Duke Clinical Microbiology Laboratory will discontinue stool culture and antigen testing, and transition to a multiplex molecular test for patients with community-onset gastroenteritis with signs of or at risk for severe disease and who are ≤ 3 days from hospital admission. For admitted patients with new hospital-onset diarrhea >3 days after admission, consider *C. difficile* PCR w/ reflex to Toxin EIA (LAB253), or non-infectious causes instead. For all other patients, stool culture and antigen testing are available through LabCorp.

Tests that will be discontinued:

- Culture, Stool (LAB223) and Culture, Yersinia (LAB1288)
- Parasite Screen, Giardia and Cryptosporidium (LAB6723)

New molecular test to be added:

- **Gastrointestinal Pathogen (GIP) Panel (LAB3466)**
 - For additional test information, [Click Here](#)
 - Testing is restricted to the following populations:
 - Inpatient ≤ 3 days from admission with moderate to severe diarrhea with suspected infectious cause
 - Immunocompromised/Transplant patient

New send-out tests:

- Stool Culture, LABCORP (LAB3394)
 - Includes detection of *Salmonella sp.*, *Shigella sp.*, *Campylobacter sp.*, and Shiga-like toxin-producing *E. coli* (STEC)
- Giardia lamblia & Cryptosporidium Direct Detection EIA, LABCORP (LAB6723)
- When clinically indicated, separate cultures are also available for Yersinia, Vibrio, and Aeromonas

For Detailed Testing and Treatment Guidance:

- [Adult CustomID hyperlink](#)
- [Pediatric CustomID hyperlink](#)

Further information can be found by searching the specific lab test on the Clinical Laboratories Electronic Test Catalog: <https://testcatalog.duke.edu/>.

For clinical questions related to these changes, please contact Mark Lee, Ph.D. mark.lee624@duke.edu or Diana Alame, M.D. diana.alame@duke.edu.

For questions regarding collection supplies, please call Client Services at 919-613-8400.